Exicure Rises Following Burixafor Trial Results in Multiple Myeloma
Positive Phase 2 Data: Exicure Inc. shares surged over 65% after presenting favorable phase 2 trial results for Burixafor, an investigational drug for multiple myeloma, at the ASH Annual Meeting.
Trial Results: The trial showed that 89.5% of participants successfully collected the required number of CD34+ cells for transplantation, with rapid mobilization kinetics observed, allowing for same-day administration and apheresis.
Multiple Myeloma Overview: Multiple myeloma is a rare blood cancer affecting plasma cells in the bone marrow, leading to complications like weakened immunity and bone damage, with autologous hematopoietic cell transplantation being a standard treatment.
Comparison with Existing Treatments: Burixafor demonstrated quicker mobilization compared to current FDA-approved CXCR4 antagonists, which require overnight pre-treatment, potentially improving the efficiency of stem cell collection for patients.
Trade with 70% Backtested Accuracy
Analyst Views on XCUR
About XCUR
About the author
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
Exicure Stock Rises 41% Following Positive Phase 2 Results for Multiple Myeloma Treatment
Stock Surge: Exicure, Inc. (XCUR) shares rose 41.37% to $7.45 following positive topline results from its Phase 2 study of burixafor for multiple myeloma.
Efficacy and Safety Signals: The study indicated promising efficacy and safety, boosting investor confidence in burixafor as a potential new treatment for this challenging cancer.
Increased Trading Volume: Trading volume significantly increased as the market reacted to the favorable study results, indicating heightened investor interest.
Stock Volatility: The stock's 52-week range is between $3.20 and $9.80, highlighting the volatility often seen in early-stage biotech companies.
Crude Oil Falls 1%; AutoZone Stock Declines Following Q1 Earnings Report
U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow up 0.22%, the Nasdaq rising 0.22%, and the S&P 500 increasing by 0.23%. Energy shares led the market with a 1.5% rise, while healthcare stocks fell by 0.4%.
Notable Stock Movements: AutoZone's stock dropped 7% after disappointing earnings, while Alexander & Baldwin's shares surged 38% following a private buyout announcement. Exicure Inc. and Tronox Holdings also saw significant gains of 35% and 30%, respectively.
Commodities Update: Oil prices fell by 1.1% to $58.23, while gold increased by 0.7% to $4,248.20. Silver rose 4.5%, but copper experienced a decline of 2.2%.
Global Market Overview: European shares were mixed, with the eurozone's STOXX 600 down 0.10%, while Asian markets mostly closed lower, except for Japan's Nikkei, which rose slightly by 0.14%.
Exicure Soars Following Promising Cell-Enhancing Outcomes in Blood Cancer Study
Stock Performance: Exicure, Inc. (NASDAQ: XCUR) saw a significant increase in stock price, rising 63.23% to $8.70, with a trading volume of 13.62 million shares compared to the average of 151.41 thousand.
Clinical Trial Results: The company reported positive results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and G-CSF for mobilizing hematopoietic progenitor cells in multiple myeloma patients, with approximately 90% of participants achieving the primary endpoint.
Mechanism of Action: Burixafor is an investigational small molecule that enhances the mobilization of HPCs by blocking CXCL12 binding to CXCR4 receptors, allowing for rapid collection of CD34+ cells from the blood.
Safety and Efficacy: The combination treatment was well tolerated with no significant adverse events, and a high percentage of participants previously treated with daratumumab still achieved the primary endpoint, indicating its effectiveness even in challenging cases.
Dow Rises More Than 100 Points as Campbell's Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones rising 0.25% while the NASDAQ and S&P 500 fell by 0.31% and 0.02%, respectively. Energy shares increased by 1.1%, while communication services stocks dropped by 0.5%.
Campbell's Co Earnings Report: Campbell's Co reported better-than-expected Q1 earnings of 77 cents per share, surpassing the analyst estimate of 73 cents, along with quarterly sales of $2.677 billion, exceeding the expected $2.657 billion.
Notable Stock Movements: Netcapital Inc saw a significant increase of 90% in its shares, while Exicure Inc surged 68% after positive trial results. Conversely, Top Wealth Group Holding Ltd's shares plummeted 69% following a public offering announcement.
Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 down 0.1%, while Asian markets mostly closed lower, with Japan's Nikkei slightly up by 0.14% and Hong Kong's Hang Seng down 1.29%.
What Critics Misunderstand About AI — and Why These Stocks Will Continue to Rise Despite Concerns
Market Overview: The S&P 500 remains stagnant as investors await the Federal Reserve's decision, struggling to reach new record highs.
Tech Sector Activity: Nvidia experiences a slight increase in stock value due to news of being able to sell AI chips to China.
Investor Sentiment: There is growing skepticism among investors regarding the profitability of significant investments in AI stocks.
Stock Performance: AI stocks are facing challenges in achieving gains, indicating that they are working harder for advancements compared to previous months.
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
Exicure Stock Rises 41% Following Positive Phase 2 Results for Multiple Myeloma Treatment
Stock Surge: Exicure, Inc. (XCUR) shares rose 41.37% to $7.45 following positive topline results from its Phase 2 study of burixafor for multiple myeloma.
Efficacy and Safety Signals: The study indicated promising efficacy and safety, boosting investor confidence in burixafor as a potential new treatment for this challenging cancer.
Increased Trading Volume: Trading volume significantly increased as the market reacted to the favorable study results, indicating heightened investor interest.
Stock Volatility: The stock's 52-week range is between $3.20 and $9.80, highlighting the volatility often seen in early-stage biotech companies.
Crude Oil Falls 1%; AutoZone Stock Declines Following Q1 Earnings Report
U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow up 0.22%, the Nasdaq rising 0.22%, and the S&P 500 increasing by 0.23%. Energy shares led the market with a 1.5% rise, while healthcare stocks fell by 0.4%.
Notable Stock Movements: AutoZone's stock dropped 7% after disappointing earnings, while Alexander & Baldwin's shares surged 38% following a private buyout announcement. Exicure Inc. and Tronox Holdings also saw significant gains of 35% and 30%, respectively.
Commodities Update: Oil prices fell by 1.1% to $58.23, while gold increased by 0.7% to $4,248.20. Silver rose 4.5%, but copper experienced a decline of 2.2%.
Global Market Overview: European shares were mixed, with the eurozone's STOXX 600 down 0.10%, while Asian markets mostly closed lower, except for Japan's Nikkei, which rose slightly by 0.14%.
Exicure Soars Following Promising Cell-Enhancing Outcomes in Blood Cancer Study
Stock Performance: Exicure, Inc. (NASDAQ: XCUR) saw a significant increase in stock price, rising 63.23% to $8.70, with a trading volume of 13.62 million shares compared to the average of 151.41 thousand.
Clinical Trial Results: The company reported positive results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and G-CSF for mobilizing hematopoietic progenitor cells in multiple myeloma patients, with approximately 90% of participants achieving the primary endpoint.
Mechanism of Action: Burixafor is an investigational small molecule that enhances the mobilization of HPCs by blocking CXCL12 binding to CXCR4 receptors, allowing for rapid collection of CD34+ cells from the blood.
Safety and Efficacy: The combination treatment was well tolerated with no significant adverse events, and a high percentage of participants previously treated with daratumumab still achieved the primary endpoint, indicating its effectiveness even in challenging cases.
Dow Rises More Than 100 Points as Campbell's Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones rising 0.25% while the NASDAQ and S&P 500 fell by 0.31% and 0.02%, respectively. Energy shares increased by 1.1%, while communication services stocks dropped by 0.5%.
Campbell's Co Earnings Report: Campbell's Co reported better-than-expected Q1 earnings of 77 cents per share, surpassing the analyst estimate of 73 cents, along with quarterly sales of $2.677 billion, exceeding the expected $2.657 billion.
Notable Stock Movements: Netcapital Inc saw a significant increase of 90% in its shares, while Exicure Inc surged 68% after positive trial results. Conversely, Top Wealth Group Holding Ltd's shares plummeted 69% following a public offering announcement.
Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 down 0.1%, while Asian markets mostly closed lower, with Japan's Nikkei slightly up by 0.14% and Hong Kong's Hang Seng down 1.29%.
What Critics Misunderstand About AI — and Why These Stocks Will Continue to Rise Despite Concerns
Market Overview: The S&P 500 remains stagnant as investors await the Federal Reserve's decision, struggling to reach new record highs.
Tech Sector Activity: Nvidia experiences a slight increase in stock value due to news of being able to sell AI chips to China.
Investor Sentiment: There is growing skepticism among investors regarding the profitability of significant investments in AI stocks.
Stock Performance: AI stocks are facing challenges in achieving gains, indicating that they are working harder for advancements compared to previous months.
